MedTrace Logo

Norepinephrine Boluses in Liver Transplantation

NCT03773276 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-12-21

No results posted yet for this study

Summary

We study the efficacy of Norepinephrine boluses on prevention of postreperfusion syndrome during living donor liver transplantation.

NE and Post-reperfusion:

On portal vein declamping, we will start rapid 500 ml 4% albumin infusion or packed RBCs (according to the anhepatic hemoglobin level 5 min before declamping) through 14 Gauge peripheral venous cannula in all patients.

NE boluses technique; We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;

* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.
* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus
* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.
* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses.

Conditions

  • Living Donor Liver Transplantation
  • Norepinephrine Bolus
  • Postperfusion Syndrome

Interventions

DRUG

Norepinephrine boluses

On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow; * If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses. * If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus * If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated. * If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Amr M Yassen, Professor · Mansoura University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2020-04-18
Completion
2020-08-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03773276 on ClinicalTrials.gov